Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab (AK104) plus SOX as neoadjuvant therapy for locally advanced gastric cancer
ChiCTR2300072695Phase 2Recruiting
- Sponsor
- The First People's Hospital of Jingzhou
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric adenocarcinoma, sponsored by The First People's Hospital of Jingzhou. Primary endpoints: Pathological complete response rate and R0 resection rate. Started Jul 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300072695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072695.